Literature DB >> 9231898

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.

S Atwell1, J B Ridgway, J A Wells, P Carter.   

Abstract

Structure-guided phage display was used to select for combinations of interface residues for antibody C(H)3 domains that promote the formation of stable heterodimers. A C(H)3 "knob" mutant was made by replacement of a small residue, threonine, with a larger one, tryptophan: T366W. A library of C(H)3 "hole" mutants was then created by randomizing residues 366, 368 and 407, which are in proximity to the knob on the partner C(H)3 domain. The C(H)3 knob mutant was fused to a peptide flag and the C(H)3 hole library was fused to M13 gene III. Phage displaying stable C(H)3 heterodimers were recovered by panning using an anti-flag antibody. Phage-selected C(H)3 heterodimers differed in sequence from the previously designed heterodimer T366W-Y407'A, and most clones tested were more stable to guanidine hydrochloride denaturation. The thermal stability of individual C(H)3 domains secreted from Escherichia coli was analyzed by differential scanning calorimetry. One heterodimer, T366W-T366'S:L368'A:Y407'V, had a t(m) of 69.4 degrees C, which is 4.0 deg.C higher than that for the designed heterodimer and 11.0 deg.C lower than that for the wild-type homodimer. The phage-selected C(H)3 mutant maintained the preference for forming heterodimers over homodimers as judged by near-quantitative formation of an antibody/immunoadhesin hybrid in a cotransfection assay. Phage optimization provides a complementary and more comprehensive strategy to rational design for engineering homodimers for heterodimerization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231898     DOI: 10.1006/jmbi.1997.1116

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  81 in total

1.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Authors:  Kannan Gunasekaran; Martin Pentony; Min Shen; Logan Garrett; Carla Forte; Anne Woodward; Soo Bin Ng; Teresa Born; Marc Retter; Kathy Manchulenko; Heather Sweet; Ian N Foltz; Michael Wittekind; Wei Yan
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

3.  Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Authors:  Christoph Spiess; Jack Bevers; Janet Jackman; Nancy Chiang; Gerald Nakamura; Michael Dillon; Hongbin Liu; Patricia Molina; J Michael Elliott; Whitney Shatz; Justin M Scheer; Glen Giese; Josefine Persson; Yin Zhang; Mark S Dennis; James Giulianotti; Prateek Gupta; Dorothea Reilly; Enzo Palma; Jianyong Wang; Eric Stefanich; Heleen Scheerens; Germaine Fuh; Lawren C Wu
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

Review 4.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

5.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.

Authors:  Christoph Spiess; Mark Merchant; Arthur Huang; Zhong Zheng; Nai-Ying Yang; Jing Peng; Diego Ellerman; Whitney Shatz; Dorothea Reilly; Daniel G Yansura; Justin M Scheer
Journal:  Nat Biotechnol       Date:  2013-07-07       Impact factor: 54.908

6.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

7.  A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.

Authors:  Lin Yu; Xi Yang; Nan Huang; Qiao-Li Lang; Qi-Lin He; Wang Jian-Hua; Ge Liang-Peng
Journal:  Cancer Biol Ther       Date:  2020-04-02       Impact factor: 4.742

Review 8.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

9.  Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Authors:  Janet Jackman; Yongmei Chen; Arthur Huang; Barbara Moffat; Justin M Scheer; Steven R Leong; Wyne P Lee; Juan Zhang; Navneet Sharma; Yanmei Lu; Suhasini Iyer; Robert L Shields; Nancy Chiang; Michele C Bauer; Diana Wadley; Merone Roose-Girma; Richard Vandlen; Daniel G Yansura; Yan Wu; Lawren C Wu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

10.  Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies.

Authors:  Yan Gong; Eric Bourhis; Cecilia Chiu; Scott Stawicki; Venita I DeAlmeida; Bob Y Liu; Khanhky Phamluong; Tim C Cao; Richard A D Carano; James A Ernst; Mark Solloway; Bonnee Rubinfeld; Rami N Hannoush; Yan Wu; Paul Polakis; Mike Costa
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.